Corvus Pharmaceuticals, Inc. CRVS
11.62
(0.18)
(1.53%)
as of 25 Sep
- Market cap
- $992.6M
- P/E
- 0.0×
Follow CRVS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(95.52%) | (32.60%) | (13.13%) | (18.98%) | |
| (57.73%) | (21.83%) | (12.18%) | (17.64%) | ||
ROIC |
(399.52%) | (602.85%) | (755.45%) | (352.49%) | |
Return on Tangible Assets |
(68.04%) | (31.16%) | (8.35%) | (13.93%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.42) | (0.39) | (0.49) | |
Free Cash Flow |
(32.21) | (32.97) | (35.14) | (45.23) | |
Capital Expenditures |
(0.14) | (0.17) | (0.23) | (0.70) | |
| Other line items | |||||
Cash ROIC |
(23.33%) | (27.80%) | (7.31%) | (10.11%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 2.15 | 1.83 | 1.54 | |
Depreciation/Fixed assets |
(5.55) | (5.64) | (3.40) | (0.52) | |
Capex/Depreciation |
0.12 | 0.14 | 0.24 | 1.60 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.39) | (0.42) | (0.39) | (0.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates